How CellPlan Unlocks The Potential Of Cord Blood Banking

Dr. Peter Hollands is the Chief Scientific Officer of Widecells Group PLC (LON:WDC) and a founding father of modern regenerative medicine. His stem cell research began at Cambridge University in the late1970’s and he continues to work at the threshold of human knowledge and understanding of stem cells and their therapeutic potential.

We talked to Dr. Hollands about his own professional journey, and about how stem cell science has progressed during his career. Dr. Hollands also shared his insights into the future of regenerative medicine and the roles of umbilical cord blood and stem cell insurance in that future.

 

Dr. Hollands, thank you for talking to us today. Please tell us a little about your professional journey to your current position as Chief Medical Officer.

I trained at Cambridge University and carried out my PhD at Cambridge University working on some of the very early ideas in modern stem cell technology. I then trained as a Clinical Embryologist and worked at the first IVF clinic in the world called Bourn Hall Clinic.

During my career I have worked as an Academic in several Universities, worked for private biotechnology and stem cell companies and worked with the NHS at Great Ormond Street Hospital for Children. All of these positions involved teaching, research and clinical work in stem cell technology.

I met João Andrade and Lopes Gil shortly after they created WideCells and I am now delighted to be the Chief Scientific Officer of the WideCells Group PLC. In November 2017 I will receive a Visiting Chair in Regenerative Medicine from the Calcutta School of Tropical Medicine, Department of Regenerative Medicine.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    WideCells Group PLC

    More articles like this

    WideCells Group PLC

    Umbilical blood injects new life into 8-month-old baby

    An 8-month-old girl who had severe combined immune deficiency (SCID) underwent a successful hematopoietic stem cell transplant surgery in Shanghai. The stem cell was taken from umbilical cord blood. Widecells Group PLC (LON:WDC) are leading a

    WideCells Group PLC

    Leukaemia: A Guide To The Cancer Of The Blood

    It is not hereditary, and it is not contagious. It is, however, one of the diseases that kills more children than many others. The word ‘leukaemia’ refers to a group of cancers that spread through the

    WideCells Group PLC

    Autism Treated With Stem Cells

    Researchers at Duke University have utilized autologous (the patient’s own) stem cell infusions to promote increased connectivity in the brain that allowed for improved communication and language abilities in children with Autism Spectrum Disorder (ASD). The

    WideCells Group PLC

    Cord blood banking industry expected to grow

    The list of decisions for new parents already seems endless but it continues to grow as new advances in medicine and technology open new doors for healthcare. Many private companies offer services for collecting and storing